Veranex is enhancing its European MedTech capabilities by acquiring Medidee


Today, Lausanne, Switzerland-based Medideeknown, a top provider of medical technology consulting services, was acquired by Veranex, the only genuinely comprehensive, global, technology-enabled service provider in the sector. With the addition of Veranex, Medidee expands and strengthens its competencies in the areas of regulatory requirements, clinical development, and quality assurance for MedTech companies throughout Europe and around the world. Medidee is a well-established European consultancy for regulatory and quality assurance services. Medidee can provide comprehensive support for the development and marketing of MedTech products as a result of its improved competency in meeting EU-MDR/IVDR criteria for medical devices and in-vitro diagnostics.

” With the acquisition of Medidee, we have significantly expanded our footprint in Europe while also significantly expanding the scale of clinical trials we can conduct”, ” The combined company will have offices and expertise across Europe, the United States and Asia, increasing our capability to help MedTech innovators achieve FDA and CE approvals and end-to-end market access for new and proven medical technologies that require.” improve patient care.”

David Dockhorn, CEO of Veranex

The company now has an unmatched footprint to provide its clients with the full range of integrated services from conception to commercialization – design, engineering, regulation, quality, pre-clinical research, clinical development, clinical operations, commercial strategy, and market access – all from a single source thanks to Medidee’s 11 locations in Europe, India, and Asia Pacific and Veranex’s 13 locations in the US, Europe, and China. One of the top three medical device consulting service providers in Europe, Medidee is uniquely positioned as a pioneer in cutting-edge fields like cybersecurity, machine learning, and digital health. The business is also skilled in doing clinical research.

“Medidee has a long-standing track record of solving regulatory, clinical and quality requirements for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories in different geographies,”

Medidee co-founders Kim Rochat, Philippe Etter and Michael Maier

“With these services and Veranex’s extensive infrastructure, we increase our knowledge and capabilities for the benefit of our clients as well as all forward-thinking firms in the EU who wish to rapidly and effectively reach the US market and other worldwide markets. The co-founders, who will have new roles in the combined business, continued, “We look forward to offering these additional skills and competencies.

Next Post

Exscientia's precision medicine AI platform is being further assessed by Blood Cancer Discovery - Journal to enhance patient outcomes

Exscientia, ETH Zurich, Medical University of Vienna, and the Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences today announced a new publication from Prof. Berend Snijder’s lab entitled “Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing” in Blood Cancer Discovery, a journal of […]